Resources

A phase I study of an innovative drug used in the treatment of patients with a new coronavirus infection (COVID-19) has been completed. The final report has been prepared.

CPD has developed a strategy for preclinical and clinical study of a new prolonged finished dosage form in order to further obtain a registration certificate.

CPD has received permission from the Ministry of Health of Russia and is starting to conduct the clinical part of the bioequivalence study of a drug used in the treatment of inflammatory and degenerative diseases of the musculoskeletal system, pain syndrome from the spine (lumbago, neuralgia, myalgia,…

The phase III study has been completed and the final report of the study on the evaluation of the efficacy and safety of the drug used in the treatment of attention deficit hyperactivity disorder (ADHD) has been prepared in children 6−12 years of age with different dosage regimens.

The SRV organized three studies of user testing of the text of the instructions for medical use (leaflet) of the medicinal product for medical use.

CPD employees have prepared a number of protocols and related documents for obtaining permission from the Ministry of Health of the Russian Federation to conduct bioequivalence studies of medicines.

CPD has received permission from the Ministry of Health of Russia to conduct bioequivalence studies of a series of drugs.

CPD employees have prepared a number of protocols and other documents necessary to obtain permission from the Ministry of Health of the Russian Federation to conduct drug research.